Our Take
A 44-patient Phase III trial met its primary endpoint; the real news is priority review status, which signals FDA confidence in the data path but commits nothing about approval.
Why it matters
oHCM in adolescents is under-treated and Camzyos is the only approved drug in its class for symptomatic disease. A pediatric indication would expand a drug already prescribed to roughly 25,000 US patients (company-reported) into a younger population with documented functional decline.
Do this week
Cardiologists: alert pediatric patients and families with confirmed oHCM who meet symptom criteria that a new treatment option is moving through FDA review; expect a decision in 30 months.
FDA grants priority review to BMS adolescent heart drug application
Bristol Myers Squibb received FDA acceptance of a supplemental new drug application (sNDA) to expand Camzyos (mavacamten) to adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The regulator assigned priority review status and set a Prescription Drug User Fee Act (PDUFA) target decision date of 30 September 2026.
The application rests on data from the Phase III SCOUT-HCM trial, a randomized, double-blind, placebo-controlled study that enrolled 44 adolescents. The trial met its primary endpoint: a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 versus placebo. Safety outcomes were consistent with adult data, and no adolescent participant experienced left ventricular ejection fraction (LVEF) below 50% (company-reported). The trial design included an initial 28-week placebo-controlled period, followed by a 28-week active-treatment phase, and an open-label extension lasting 144 weeks.
Camzyos is currently approved in adults with symptomatic NYHA Class II-III oHCM to improve functional capacity and symptoms. BMS reports the drug has been prescribed by more than 4,500 healthcare providers to approximately 25,000 patients in the United States.
Priority review is routine for first-in-class pediatric indications
Priority status does not predict approval; it shortens review timelines from 10 months to 6. FDA grants priority review when a drug offers a potential therapeutic advantage over existing options. In adolescent oHCM, there is a clear gap: no other disease-modifying treatment exists for symptomatic minors in this age group.
Adolescents with oHCM face reduced exercise tolerance and cumulative morbidity. Expanding Camzyos into this population would address an unmet need, but the small trial size (44 subjects) is typical for rare pediatric conditions. The real marker of confidence will be whether FDA's standard review raises safety or efficacy questions between now and September 2026.
Cardiologists should prepare families for a potential new treatment path
If approved, Camzyos would become the first oral, disease-modifying option for adolescents with symptomatic oHCM. Pediatric cardiologists managing symptomatic patients in the eligible age band should begin conversations with families about the approval timeline and candidacy criteria (NYHA Class II-III symptoms, documented outflow obstruction). The FDA decision is still 30 months away, but documentation of symptom severity and hemodynamic burden now will streamline evaluation if the indication expands.